[CAS NO. 1435265-06-7]  HCH6-1

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1435265-06-7]

Catalog
HY-101283
Brand
MCE
CAS
1435265-06-7

DESCRIPTION [1435265-06-7]

Overview

MDLMFCD32197174
Molecular Weight469.53
Molecular FormulaC28H27N3O4
SMILESO=C(N[C@H](C(N[C@@H](C(OC)=O)CC1=CC=CC=C1)=O)CC2=CNC3=C2C=CC=C3)C4=CC=CC=C4

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE


Summary

HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1) . HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases [1] .


IC50 & Target

IC50: Formyl peptide receptor 1 (FPR1) [1]


In Vitro

In a cell-impermeable cytochrome c reduction assay, HCH6-1 significantly inhibits superoxide anion generation in fMLF (FPR1 agonist)-activated neutrophils with an IC 50 of 0.32 μM. HCH6-1 has fewer inhibitory effects in WKYMVm (dual FPR1/FPR2 agonist)- and MMK1 (FPR2 agonist)-activated neutrophils, with IC 50 s of 4.98±0.27 μM and 17.68±2.77 μM, respectively [1] .
HCH6-1 does not induce LDH release even at 30 μM, so it does not have cytotoxic effects in human neutrophils. HCH6-1 does not alter the level of xanthine/xanthine oxidase superoxide anion and DPPH radical in cell-free systems [1] .
HCH6-1 significantly inhibits elastase release in fMLF-activated neutrophils, with an IC 50 of 0.57 μM. However, in neutrophils triggered by WKYMVm or MMK1, HCH6-1 inhibits elastase release at higher concentrations, with IC 50 s of 5.22±0.69 μM and 10.00±0.65 μM, respectively [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

HCH6-1 (intraperitoneal injection; 50 mg/kg; 1 h before LPS spray or 30 min after LPS spray) alone does not induce airspace inflammation. HCH6-1 pretreatment reduces inflammatory cell infiltration and distortion of pulmonary architecture in the presence of LPS. HCH6-1 posttreatment shows inhibitory effects on neutrophil accumulation and lung damage in LPS-induced ALI mice [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (20-25 g, 7-8 weeks old) [1]
Dosage: 50 mg/kg
Administration: Intraperitoneal injection; 50 mg/kg; 1 h before LPS spray or 30 min after LPS spray
Result: Ameliorated ALI in LPS-induced mice.
HCH6-1-mediated decreasing of neutrophil recruitment serves as a protective mechanism in ALI mice.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 532.45 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1298 mL 10.6489 mL 21.2979 mL
5 mM 0.4260 mL 2.1298 mL 4.2596 mL
10 mM 0.2130 mL 1.0649 mL 2.1298 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.08 mg/mL (4.43 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.43 mM); Clear solution

* All of the co-solvents are available by MCE.